💨 Abstract

Esperion Therapeutics Inc. reported a loss of $40.5 million in Q1 2025, with a per-share loss of 21 cents, missing Wall Street's expected loss of 18 cents per share. However, the Ann Arbor, Michigan-based biopharmaceutical company exceeded revenue expectations, posting $65 million compared to the forecasted $57.7 million.

Courtesy: wtop.com

Summarized by Einstein Beta 🤖